Weight Loss Pen
Wegovy
🖋️ Wegovy Weight Loss Pen is an innovative weekly injectable designed to support sustainable weight management. Its active ingredient, Semaglutide, effectively controls hunger and appetite, ideal for those seeking behavioral change and long-term weight loss.
⏳ Key Benefits of Wegovy:
✔️ Reduces appetite and increases feelings of fullness
✔️ Easy-to-use once-weekly injection
✔️ Clinical studies show up to 17%* weight loss from starting body weight
🖋️ User-Friendly Pen Design:
✔️ Designed for self-injection
✔️ Pre-filled pen, no mixing required
✔️ Compact, portable, and easy to store ✈️
Shipping
Discreet shipping within Thailand — packaging does not identify the product. Customers can review shipping and return conditions per our store policy. Contact our team for any questions.
Product Description
Weight loss injections are a medically proven innovation for effective weight management. Wegovy is an injectable weight loss medication in the GLP-1 Receptor Agonist class containing Semaglutide 2.4 mg/week, manufactured by Novo Nordisk.
📊 Key Statistics
- Wegovy is approved for individuals with BMI ≥30 or BMI ≥27 with comorbidities
- The STEP 1 trial showed an average weight loss of 14.9% of body weight
- The SELECT trial demonstrated significant reduction in cardiovascular events
- See other weight loss medications in the Weight Loss collection
🏭 Wegovy is manufactured by Novo Nordisk. It works via GLP-1 Receptor Agonist mechanism — stimulating GLP-1 to reduce appetite, increase satiety, and slow gastric emptying.
⚠️ Wegovy must be used under medical supervision and should be combined with dietary changes and exercise.
About Wegovy
What is Wegovy?
Wegovy is a subcutaneous injectable weight loss pen containing Semaglutide 2.4 mg/week as its active ingredient. It belongs to the GLP-1 Receptor Agonist drug class and is manufactured by Novo Nordisk.
Semaglutide mimics the GLP-1 hormone in the body, working through three mechanisms: (1) reducing appetite by acting on the brain, (2) increasing feelings of fullness sooner, and (3) slowing gastric emptying to prolong satiety.
Wegovy is a high-dose Semaglutide (2.4 mg) specifically approved for weight management, unlike Ozempic which is approved for type 2 diabetes.
What is Wegovy used for?
Weight management: Wegovy is for individuals with BMI ≥30 (obesity) or BMI ≥27 with at least one comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea.
Cardiovascular risk reduction: The SELECT trial showed Semaglutide 2.4 mg reduced MACE (major adverse cardiovascular events) risk by 20%.
Must be used alongside: Dietary modification, calorie reduction, and regular exercise.
How to Use Wegovy / Dosage
How to use: Inject subcutaneously once weekly in the abdomen, thigh, or upper arm. Rotate injection sites each time.
Dose escalation:
- Month 1: 0.25 mg/week
- Month 2: 0.5 mg/week
- Month 3: 1.0 mg/week
- Month 4: 1.7 mg/week
- Month 5 onwards: 2.4 mg/week (target dose)
Important: Gradual dose escalation helps minimise gastrointestinal side effects.
Side Effects of Wegovy
Common side effects:
- Nausea (most common, usually improves as the body adjusts)
- Vomiting
- Diarrhoea
- Constipation
- Abdominal pain
Rare but serious side effects:
- Pancreatitis — severe abdominal pain, seek medical help immediately
- Gastroparesis (abnormally slow stomach emptying)
- Gallbladder problems
- Acute kidney injury (from dehydration due to vomiting/diarrhoea)
Contraindications & Precautions
Do not use:
- Personal or family history of Medullary Thyroid Carcinoma (MTC) or MEN2 syndrome
- History of pancreatitis
- Pregnant or planning pregnancy
- Breastfeeding
- Allergy to Semaglutide or any component
Use with caution:
- Kidney or liver problems
- History of depression or suicidal thoughts
- Diabetic retinopathy
- Do not use with other GLP-1 RAs such as Ozempic
How Does Wegovy Compare to Other Weight Loss Medications?
Wegovy vs. Mounjaro (Tirzepatide): Mounjaro is a dual GIP/GLP-1 agonist acting on two receptors. Trials show Tirzepatide achieves greater weight loss than Semaglutide (up to 22.5%). Mounjaro is for those seeking maximum weight loss results.
Wegovy vs. Ozempic: Same active ingredient (Semaglutide) but different doses — Ozempic max 2.0 mg for diabetes, Wegovy 2.4 mg specifically for weight management. Wegovy is approved for weight loss; Ozempic is approved for type 2 diabetes.
How Much Weight Can Wegovy Help You Lose?
In the STEP 1 trial, Wegovy 2.4 mg users lost an average of 14.9% of their body weight (approximately 15 kg for a 100 kg individual) over 68 weeks.
Results timeline:
- 4–8 weeks: Initial weight loss begins; appetite reduction noticeable
- 12–16 weeks: Steady weight loss continues as target dose of 2.4 mg is reached
- 6–12 months: Full effect visible; maximum weight loss achieved
Important: Results vary between individuals. Must be combined with dietary changes and regular exercise.
Where Can I Buy Wegovy?
Wegovy is a prescription medication. You can order online from Intimo Life.
Can I buy Wegovy online?
Yes. Order through Intimo Life — select the product, consult with a licensed pharmacist online, and receive your medication at home.
Do I need a prescription?
A doctor's prescription is not required, but the medication must be dispensed by a licensed pharmacist. At Intimo Life, our pharmacist will review your symptoms and health history to confirm suitability before shipping.
How does Intimo Life ship orders?
We deliver nationwide in Thailand with discreet, temperature-controlled packaging for injectable medications — no product names on the outside.
⚠️ Disclaimer
The information on this page is for general informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment from a qualified doctor or pharmacist. If you have any questions about your symptoms or medication, always consult a doctor or pharmacist first.
Frequently Asked Questions
Both contain Semaglutide but differ in dose and indication. Ozempic max 2.0 mg is approved for type 2 diabetes. Wegovy 2.4 mg is specifically approved for weight management.
In the STEP 1 trial, users lost an average of 14.9% body weight over 68 weeks, compared to 2.4% with placebo. Individual results vary.
Nausea is the most common side effect, especially during the initial phase and dose increases. It usually improves within 4–8 weeks as the body adjusts. Gradual dose escalation helps minimise this.
Studies show that about two-thirds of lost weight may be regained within a year of stopping Semaglutide. Maintaining healthy eating habits and regular exercise is crucial for long-term results.
Unused Wegovy pens must be refrigerated (2–8°C). Do not freeze. Once in use, they can be stored at room temperature (up to 30°C) for up to 28 days. Protect from light and heat.
Mounjaro (Tirzepatide) is a dual GIP/GLP-1 agonist. Trials show greater weight loss than Wegovy (up to 22.5% vs 14.9%). However, both are highly effective. The choice depends on your doctor's recommendation and individual factors.
Become a member of our store to receive news and exclusive discounts.
